GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » PensionAndRetirementBenefit

Vidac Pharma Holding (STU:T9G) PensionAndRetirementBenefit : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding PensionAndRetirementBenefit?

Vidac Pharma Holding's PensionAndRetirementBenefit for the quarter that ended in Jun. 2024 was €0.00 Mil.


Vidac Pharma Holding PensionAndRetirementBenefit Historical Data

The historical data trend for Vidac Pharma Holding's PensionAndRetirementBenefit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding PensionAndRetirementBenefit Chart

Vidac Pharma Holding Annual Data
Trend Dec21 Dec22 Dec23
PensionAndRetirementBenefit
- - -

Vidac Pharma Holding Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24
PensionAndRetirementBenefit - - - - -

Vidac Pharma Holding PensionAndRetirementBenefit Calculation

PensionAndRetirementBenefit is the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.


Vidac Pharma Holding Business Description

Traded in Other Exchanges
N/A
Address
Wenlock Road, 20-22, London, GBR, N1 7GU
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines